A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001 The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg once daily) plus sildenafil (20 mg TID) as compared to sitaxsentan monotherapy by determining time to clinical wo...

• Country None
• organs None
• Specialty None

Oral Revatio in Pediatric PAH - Long-term follow-on Study to A1481131 The primary objective is to assess the safety and tolerability of oral sildenafil in the chronic treatment of pediatric subjects with PAH.

• Country None
• organs None
• Specialty None

A PHASE 2B, PARALLEL, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK QD ADMINISTRATION OF PF-00610355 CRC-749 DPI IN PATIENTS WITH MODERATE COPD To test all doses (100, 300 and 600 µg QD) of PF-00610355 and salmeterol 50 µg (BID) for superior efficacy on trough FEV1 vs placebo at Week 6.

• Country None
• organs None
• Specialty None

A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF A FESOTERODINE FLEXIBLE DOSE REGIMEN IN ELDERLY PATIENTS WITH OVERACTIVE BLADDER To compare the efficacy, in terms of a reduction of urgency episodes, of 12-weeks flexible dose Fesoterodine relative to placebo in elderly subjects with OAB.

• Country None
• organs None
• Specialty None